This study is an open-label study that will evaluate SAGE-718 on the cognitive effects in subject with early manifest Huntington's Disease (HD). The subject will be on study drug for a year. At clinic visits, participants will take the IP under staff supervision, followed by assessments of cognitive function, health-related function and quality of life, and neuropsychiatric symptoms.